Australia’s Therapeutic Goods Administration is consulting on stronger labeling requirements for listed medicines containing vitamin B6. The concern is that excessive or cumulative intake can increase the risk of peripheral neuropathy, which may result in severe, debilitating and potentially long-term nerve damage.

Currently, vitamin B6 products providing more than 10 mg equivalent pyridoxine per day must warn consumers to stop taking the products and see a healthcare practitioner if they experience tingling, burning or numbness.

The regulator is now proposing to tighten warning statements as part of its wider regulatory oversight for vitamin B6. This follows its decision to mandate that, from June 2027, all vitamin B6 supplements with a recommended daily dose of over 50 mg and up to 200 mg or less be classified as ‘pharmacist-only’ (Schedule 3) products from June 2027.

The TGA has proposed three options for strengthening the warning statements of vitamin B6 supplements and has opened a public consultation, which closes on Nov. 25.

The proposal covers pyridoxine hydrochloride, pyridoxal 5-phosphate and pyridoxal 5-phosphate monohydrate (9-5-P).

Why it matters: The issue is not limited to high-dose, single-ingredient B6 products. Consumers may accumulate vitamin B6 across multivitamins, magnesium products, energy formulas, stress supplements and sports-nutrition products without recognizing the combined intake. Manufacturers therefore need to review total daily exposure across portfolios, including alternate ingredient names such as pyridoxine and P-5-P.

Vireo Systems plans to manufacture its CreaBoost creatine monohydrate in the United States. The project is backed by an investment of more than $20 million that will create over 30 jobs at parent company Vireo Systems’ Nebraska facility.

“CreaBoost’s premium specification was previously manufactured by a single international partner and imported into the United States,” said Kevin Kerr, director of strategic initiatives, CreaBoost. “Domestic production will serve both global and U.S. markets, with an initial focus on domestic demand. In the near future, we will be announcing several significant strategic partnerships that have already embraced the opportunity to have domestically made creatine.”

Kerr noted that the brand has worked with its overseas partner to refine CreaBoost’s premium specification through improved sourcing and manufacturing, resulting in a highly pure creatine with improved dissolvability. The brand and its enhanced purity specification launched in May 2026.

“Format development, and innovative dosing and delivery options, have been ongoing — the improved dissolvability opened the door to great-tasting, stable new formats across the line,” Kerr said.

Why it matters: US production of creatine monohydrate will offer brands shorter lead times, improved traceability and a differentiated country-of-origin proposition. It may also reduce exposure to freight disruption, tariffs and geopolitical supply risk. If the economics work, this investment could encourage more regional production of high-volume supplement ingredients and intensify competition among established premium creatine suppliers.

Consumers have more wellness products to choose from than ever, but many remain dissatisfied with what’s lining retail shelves, particularly when it comes to longevity, mental health and mobility, according to McKinsey & Company’s latest wellness research.

McKinsey’s Future of Wellness 2027 report found that, when choosing wellness products, US consumers placed effectiveness on equal footing with price, followed by quality. Among the biggest wellness spenders, however, effectiveness and quality ranked ahead of cost.

McKinsey divided these consumers into two groups, ‘maximalist optimizers’ and ‘confident enthusiasts.’ Together they accounted for 35% of wellness consumers but 55% of spending.

For both groups, clear ingredient labeling was among the five most important considerations when purchasing vitamins, minerals, supplements and over-the-counter products.

“One reason those gaps persist: the bar for what consumers consider effective keeps rising,” the authors wrote.

Why it matters: Evidence is moving from a technical support function to a commercial differentiator. Brands targeting healthy aging, cognition, mood, joint health or mobility will need human clinical data, relevant endpoints and doses that match the finished product.

Dining and Cooking